Readit NewsThe doctors are trying to help people, the execs are being greedy while doing it. Leadership doesn’t get the benefit of the doubt at this point.
Go up too. https://hms.harvard.edu/news/deaths-rose-emergency-rooms-aft...
Part of the problem of modern society is that statistical murder of thousands is treated as less of a crime than a normal murder of one person.
The study you linked concerns whether the hospital is owned by a nonprofit or by a private equity group.
The question in this study is whether physicians work for their own practice or for the hospital directly, regardless of the ownership of the hospital.
That would cause a lot of pain for those shareholders, but would that be somewhat contained given the public "AI" companies for the most part have strong businesses outside of AI? Or are these market caps at this point so large for some of these AI public companies that anything that happens to them will cause some kind of contagion? And then the follow up is if the private AI companies collapse en masse is that market now also so big that it would cause contagion beyond venture capital and their investors (fully aware that pensions and the such are material investors in VC funds, but they're diversified so even though they'd see those losses maybe the broader market would keep them from taking major hits).
Not giving an opinion here, though my knee jerk is to think we're due for a massive drop, but I've literally been saying that for so long that I'm starting to (stupidly) think this time is different (which typically is when all hell breaks loose of course).
Also keep in mind that the biggest companies during that bubble had peak market caps of ~500B and then lost ~90%, so 400-500B in losses each and total internet related losses of a couple trillion. If NVDA lost 90%, it would be down 4 trillion dollars, or twice that total just by itself.
AI company valuations collapsing would have meaningful impacts on the broader market. Big pension/mutual funds are important sources of capital across every sector, and if they're taking big losses on NVDA, GOOG, and a portfolio of privates, it will have a chilling effect on their other activity.
I'm guessing this is rarely tested since animal modeling is usually a gating factor for human testing?
The catch here is that only two targets (PD(L)-1 and CTLA-4) turned out to work well in humans. All of the other immunotherapies that looked mediocre preclinically turned out to also be mediocre or entirely ineffective in humans.
I can’t speak to the pharma side as much, but since the 174 issue is most painful for companies with liquidity issues, I doubt it has a huge impact on them.
The claimed increase in ridership is modest (18%) off a low baseline (0 service on weekends) and occurred over a long time period (pre-pandemic to today.) They also expanded service during that period, which probably fully explains the increase in ridership. Certainly the reduction in fare ($1-->0) is nice for some people, but it's hard to imagine that it is actually decisive for a large portion of trips.
The estimates of traffic reduction and CO2 reduction just quote the city's numbers without establishing that "traffic cleared, and so did the air."
Key paragraphs:
> In 2021, the city starting [sic] running more buses, streamlining routes and seriously considering waiving the $1 fares. In 2023, the City Council voted to pay for a two-year fare-free pilot with Covid-19 relief funds.
...
> Ridership eventually grew to 118 percent of prepandemic levels, compared to the average nationally transit ridership-recovery levels of 85 percent.